Novartis (NVS) and Antares Therapeutics Partner for $1.9 Billion to Develop Novel, 'Undruggable' Cancer Therapeutics
Novartis Bets Big on Exclusive Covalent Platform
Novartis (NVS) has entered into a $1.9 billion partnership with Antares Therapeutics to tackle cancer-causing proteins that have been difficult to target with existing technologies. Under the agreement, Novartis will provide Antares with an upfront payment of $105 million (USD) and potentially up to $1.8 billion (USD) in future option fees and milestone payments, as well as royalties. Novartis's significant upfront investment is aimed at securing access to Antares' covalent drug design platform to revolutionize its oncology pipeline. This strategic move seeks to overcome the limitations of existing therapies in addressing drug resistance and to maximize the duration of therapeutic effects.
Antares: A Spin-Out with Proven Technology
Antares Therapeutics is a precision biotech company that spun out of Scorpion Therapeutics in 2025, following Eli Lilly's (LLY) acquisition of Scorpion's PI3KΞ± inhibitor pipeline for $2.5 billion. At that time, key research personnel, a covalent drug screening library, and an AI-driven chemical proteomics platform were transferred to Antares, establishing its technological foundation. Antares had already demonstrated its capabilities by conducting a $75 million joint research project with AstraZeneca (AZN) and securing a $553 million deal with Pierre Fabre. Novartis recognized the platform's consistency and reliability and chose to partner with Antares as the first partner after the spin-out.
Targeting 'Undruggable' Cancer Targets and the Dawn of Personalized Medicine
The goal of this collaboration is to discover first-in-class therapies for cancer targets that have been classified as 'undruggable' due to the absence of binding pockets. Antares will use computational chemistry and proteomics to identify candidate molecules, and Novartis will have the exclusive option to conduct clinical trials and commercialize the resulting therapies. This is expected to usher in a new era of precision medicine, providing cancer patients who have not benefited from targeted therapies with treatments that reduce side effects and maximize survival rates.
Validating Biotech Value and Setting a New Standard for High-Value Deals
Shortly after its establishment, Antares secured $177 million in Series A funding and, within a year, finalized a mega-deal with a major pharmaceutical company, demonstrating the commercial value of its platform. The funds secured through this partnership will accelerate the development of Antares' independently developed drug pipeline, with the goal of initiating Phase 1 trials by 2026. For investors, this serves as a prime example of how the spin-out and early licensing of promising platform technologies can lead to rapid value creation. This is expected to stimulate investment in the biotech sector and intensify competition among major pharmaceutical companies for joint research opportunities.
This agreement represents a strategic move by major pharmaceutical companies to gain a leading position in the development of innovative drugs in the global oncology market, which exceeds $200 billion annually. In the short term, it reaffirms the value of the proven covalent platform transferred from Scorpion and provides the financial resources to accelerate the entry of Antares' lead assets into Phase 1 trials by 2026. In the medium to long term, it is expected to narrow the gap with competitors such as Revolution Medicines (RVMD) and Frontier Medicines in the innovative drug market and overcome the limitations of non-covalent drugs in inducing resistance. For researchers, it will serve as a technological milestone in exploring new binding pockets for previously considered 'undruggable' targets, such as transcription factors and signaling proteins. Ultimately, the success of this deal will serve as a benchmark for future investments and collaborations between multinational pharmaceutical companies and early-stage biotech companies.
Source: FierceBiotech (rss)